Alborz Investment Co. (Public Company) was primarily founded under the name of “Yekdel” on December, 24th, of 1966 with the registration No. 11168 in the Organization for Registration of Companies and Industrial Ownership of Tehran and then turned from public to private on October, 20th, 1971, and its name was amended to Yekdel Private Joint Stock Company. Consequently, in the extraordinary general meeting dated July, 25th, 1974, it was turned from Private Joint Stock Company to Public Company. The current name of this company is Alborz Investigation Co. (Public Company).
The main activity of this company, based on the second article of its memorandum of association is: investing and contributing in firms and production, commercial and construction companies as well as trading securities and performing any legal commercial activity related to the scope of this company.
Alborz Investment Group was established in 1966 with a focus on production and distribution of medicines,
detergents and foodstuff. Since its inception, the company has demonstrated its capabilities as a leading and innovative group. Among the most important companies of Alborz Investment Group in 1970s are Tolid Darou, Iran Darou, KBC, which are manufacturers of pharmaceutical, cosmetic and health products with world-class brands, Toli Pers, the first manufacturer of washing powder with an Iranian brand (Shooma and Darya), Keyvan, one of the most famous confectionery companies, and Pakhsh Alborz with the Most extensive distribution channel of health products in Iran. In recent years, the strategy of Alborz Investment Group has been the focus on pharmaceutical industry and exit from other activities. Based on this strategy, production chain consisting of production of raw materials and distribution of products has been developed in the Group companies. Alborz Investment Group, as the first investment company to be listed on the Teh- ran Stock Exchange, with more than 18,000 real and legal shareholders, 13 subsidiary companies (which are reputable companies listed on the Stock Exchange), and over 3200 skilled and experienced personnel, has undertaken a considerable part of production and supply of pharmaceuticals in the country.